Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Neutherapeutics LLC
Profile last edited on: 9/27/23      CAGE: 8AXQ4      UEI: CSFGFLL3PL67

Business Identifier: Vision: to prevent, halt and cure neurodegenerative diseases and transform lives.
Year Founded
2019
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2222 East Drachman Street
Tucson, AZ 85719
   (520) 549-1038
   N/A
   www.neutherapeutics.com
Location: Single
Congr. District: 07
County: Pima

Public Profile

Under development by Neutherapeutics LLC,. Allopregnanolone is a unique, clinical-stage, regenerative treatment for Alzheimer’s Disease and other neurodegenerative diseases with the potential not only to halt but to reverse the disease's progression. The approach is currently undergoing a Phase 2b study (REGEN-BRAIN©) in patients with mild Alzheimer’s Dise

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$1
Phase II Dollars
$1,337,363
Total Awarded
$1,337,364

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $2,536,705
Project Title: PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
0 1 NIH $505,836
Project Title: Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease

Key People / Management

  Roberta D Brinton -- Founder and President

  Mark Drew -- Chief Operations Officer

  Gerson Hernande -- Chief Clinical Trials Officer

  John Rinehart -- Chief Executive Officer

  Kath Rodgers -- Chief Science Officer

Company News

There are no news available.